SUBSCRIBE
SUBSCRIBE

RayzeBio

NEWS
Pictured: Nasdaq signage and building in New York City
Deals
RayzeBio’s $311M, Neumora’s $250M IPOs Among Biotech’s Largest This Year
The two biotech companies announced initial public offering pricing Thursday, respectively, with shares beginning trading Friday and valued at more than $560 million cumulatively.
September 15, 2023
 · 
2 min read
 · 
Kate Goodwin
male hands with wrist watch is considered American dollars. Hands holding dollar cash. 1000 dollars in 100 bills in a man's hand close-up on a dark background. hundred
Business
Money on the Move: Sparing Vision, RayzeBio, Nimbus and More Garner Funds
This week was rife with Series financings, which channeled money into innovative treatments for immune diseases and cancers, genomic treatments and precision healthcare.
September 14, 2022
 · 
5 min read
 · 
Tristan Manalac
Business
RayzeBio-Partnered Startup Focused on Bringing Radiopharmaceuticals to China
Ablaze has aligned itself with RayzeBio, giving Ablaze a solid start with an in-licensing agreement to bring Rayze’s products to the greater China market.
November 30, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
Money on the Move: June 9-15
Each week more money pours into the biopharma world. Here’s a peek at who’s getting a taste of fresh funds this week.
June 16, 2021
 · 
4 min read
 · 
Kate Goodwin
Business
Cash is King for Up-and-Coming Biotechs: Four Financing Rounds Announced Today
Umoja Biopharma, Alentis Therapeutics, RayzeBio and Camp4 Therapeutics are ramping up on series funds.
June 15, 2021
 · 
4 min read
 · 
Kate Goodwin
Load More
JOBS
IN THE PRESS
Press Releases
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
June 11, 2025
 · 
3 min read
Deals
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
February 26, 2024
 · 
5 min read
Deals
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
February 12, 2024
 · 
6 min read
Deals
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
December 26, 2023
 · 
15 min read
Business
RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
 · 
8 min read
Biotech Beach
RayzeBio to Participate in Upcoming Investor Conferences in November 2023
November 6, 2023
 · 
1 min read
Business
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
November 1, 2023
 · 
4 min read
Policy
FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs
October 24, 2023
 · 
5 min read
Biotech Beach
RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress
October 18, 2023
 · 
4 min read
Deals
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 19, 2023
 · 
3 min read
Load More